Companies Dynavax Technologies
Dynavax Technologies (DVAX): executive pay, fiscal 2024
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Dynavax Technologies’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers32nd pct.Of 20 peer CEOs
CEO pay, last three years
- $5,594,000FY2022
- $5,810,736FY2023
- $8,210,775FY2024
CEO total pay was $8,210,775 in fiscal 2024, up from $5,810,736 in fiscal 2023.
FY2024: salary $835,001 · bonus $0 · stock awards $4,902,150 · option awards $1,824,299
Executives and directors
John Slebir · General CounselKelly MacDonald · CFORobert Janssen · SVPRyan Spencer · CEODavid Novack · PresidentBrent MacGregor · Independent DirectorDaniel L. Kisner · Independent DirectorElaine Sun · Independent DirectorEmilio Emini · Independent DirectorFrancis R. Cano · Independent DirectorJulie Eastland · Independent DirectorLauren Silvernail · Independent DirectorPeggy V. Phillips · Independent DirectorPeter R. Paradiso · Independent DirectorScott Myers · Chair of the Board
Frequently asked questions
Who was the highest-paid executive at Dynavax Technologies in fiscal 2024?
As disclosed, Ryan Spencer (Chief Executive Officer and Director) was the highest-paid executive at Dynavax Technologies in fiscal 2024, with total compensation of $8,210,775.
How does Dynavax Technologies's chief executive pay compare to its disclosed peer group?
As disclosed, Ryan Spencer's total compensation ranked at the 32nd percentile of Dynavax Technologies's disclosed peer group.
How did shareholders vote on Dynavax Technologies's executive compensation?
As disclosed, 92.38% of shareholders supported Dynavax Technologies's executive compensation in the latest say-on-pay vote.
How much does Dynavax Technologies spend in total on board compensation for fiscal 2024?
As disclosed, Dynavax Technologies reported total board compensation of $1,061,590 for fiscal 2024.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Ryan Spencer | $835,001 | $0 | $4,902,150 | $1,824,299 | $641,907 | $0 | $7,418 | $8,210,775 |
| Chief Executive Officer and Director | ||||||||
| David Novack | 593,108 | 0 | 2,016,121 | 750,253 | 364,762 | 0 | 7,443 | 3,731,687 |
| President and Chief Operating Officer | ||||||||
| John Slebir | 530,000 | 0 | 1,485,500 | 552,818 | 271,625 | 0 | 7,504 | 2,847,447 |
| Senior Vice President and General Counsel | ||||||||
| Kelly MacDonald | 480,098 | 6,642 | 1,379,435 | 513,331 | 239,408 | 0 | 7,353 | 2,626,267 |
| Senior Vice President and Chief Financial Officer | ||||||||
| Robert Janssen | 542,291 | 0 | 1,060,944 | 394,870 | 277,924 | 0 | 7,504 | 2,283,533 |
| Chief Medical Officer and Senior Vice President | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2024 total | FY2023 total | FY2022 total | Δ FY2023→2024 |
|---|---|---|---|---|
| Ryan Spencer | $8,210,775 | $5,810,736 | $5,594,000 | ↑ +2,400,039 |
| David Novack | 3,731,687 | 2,993,331 | 2,779,823 | ↑ +738,356 |
| John Slebir | 2,847,447 | — | — | — |
| Kelly MacDonald | 2,626,267 | 2,065,805 | 1,793,266 | ↑ +560,462 |
| Robert Janssen | 2,283,533 | 1,883,323 | 1,710,780 | ↑ +400,210 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
We believe our NEOs' compensation should align our executives' interests with that of our stockholders over the long-term through achievement of strategic corporate objectives that are fundamental to our business and that are intended to create long-term stockholder value. Our executive compensation programs are designed to be competitive within our industry and within our peer group to enable us to attract, motivate, reward, and retain outstanding talent.
| CEO STI target (% of salary) | 75% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Alpine |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2024
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| John Slebir | OPTION | 2024-02-15 | — | — | 70,000 | — | $552,818 |
| Ryan Spencer | PSU | 2024-02-15 | 82,500 | 165,000 | — | 330,000 | 2,842,950 |
| Kelly MacDonald | PSU | 2024-02-15 | 23,215 | 46,430 | — | 92,860 | 799,989 |
| David Novack | — | 2024-02-15 | — | — | 67,860 | — | 846,893 |
| Kelly MacDonald | — | 2024-02-15 | — | — | 46,430 | — | 579,446 |
| John Slebir | PSU | 2024-02-15 | 25,000 | 50,000 | — | 100,000 | 861,500 |
| Kelly MacDonald | OPTION | 2024-02-15 | — | — | 65,000 | — | 513,331 |
| Ryan Spencer | OPTION | 2024-02-15 | — | — | 231,000 | — | 1,824,299 |
| Ryan Spencer | — | 2024-02-15 | — | — | 165,000 | — | 2,059,200 |
| Robert Janssen | OPTION | 2024-02-15 | — | — | 50,000 | — | 394,870 |
| David Novack | OPTION | 2024-02-15 | — | — | 95,000 | — | 750,253 |
| Robert Janssen | — | 2024-02-15 | — | — | 35,710 | — | 445,661 |
| Robert Janssen | PSU | 2024-02-15 | 17,855 | 35,710 | — | 71,420 | 615,283 |
| John Slebir | — | 2024-02-15 | — | — | 50,000 | — | 624,000 |
| David Novack | PSU | 2024-02-15 | 33,930 | 67,860 | — | 135,720 | 1,169,228 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| John Slebir | $0 | $861,500 | $552,818 | 60.9% |
| Ryan Spencer | 0 | 2,842,950 | 1,824,299 | 60.9% |
| Kelly MacDonald | 0 | 799,989 | 513,331 | 60.9% |
| David Novack | 0 | 1,169,228 | 750,253 | 60.9% |
| Robert Janssen | 0 | 615,283 | 394,870 | 60.9% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2024
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Robert Janssen | Option | 4,167 | 12.74 | — |
| Robert Janssen | RSU | 4,333 | — | 55,332 |
| John Slebir | Option | 4,445 | 12.74 | — |
| John Slebir | RSU | 4,666 | — | 59,585 |
| Kelly MacDonald | Option | 5,028 | 12.74 | — |
| Kelly MacDonald | RSU | 5,333 | — | 68,102 |
| David Novack | Option | 8,334 | 12.74 | — |
| David Novack | RSU | 8,833 | — | 112,797 |
| Robert Janssen | PSU | 13,000 | — | 166,010 |
| John Slebir | PSU | 14,000 | — | 178,780 |
| Kelly MacDonald | PSU | 16,000 | — | 204,320 |
| Ryan Spencer | Option | 19,445 | 12.74 | — |
| Ryan Spencer | RSU | 20,833 | — | 266,037 |
| Robert Janssen | PSU | 24,000 | — | 306,480 |
| David Novack | PSU | 26,500 | — | 338,405 |
| John Slebir | PSU | 27,000 | — | 344,790 |
| Kelly MacDonald | PSU | 30,000 | — | 383,100 |
| Robert Janssen | Option | 31,111 | 11.12 | — |
| John Slebir | Option | 34,222 | 11.12 | — |
| Robert Janssen | RSU | 35,710 | — | 456,017 |
| Robert Janssen | PSU | 35,710 | — | 456,017 |
| Kelly MacDonald | Option | 38,890 | 11.12 | — |
| Kelly MacDonald | RSU | 46,430 | — | 592,911 |
| Kelly MacDonald | PSU | 46,430 | — | 592,911 |
| David Novack | PSU | 48,500 | — | 619,345 |
| John Slebir | RSU | 50,000 | — | 638,500 |
| John Slebir | PSU | 50,000 | — | 638,500 |
| Robert Janssen | Option | 50,000 | 12.48 | — |
| David Novack | Option | 58,334 | 11.12 | — |
| Ryan Spencer | PSU | 62,500 | — | 798,125 |
| Kelly MacDonald | Option | 65,000 | 12.48 | — |
| David Novack | RSU | 67,860 | — | 866,572 |
| David Novack | PSU | 67,860 | — | 866,572 |
| John Slebir | Option | 70,000 | 12.48 | — |
| David Novack | Option | 95,000 | 12.48 | — |
| Ryan Spencer | Option | 108,890 | 11.12 | — |
| Ryan Spencer | PSU | 125,000 | — | 1,596,250 |
| Ryan Spencer | RSU | 165,000 | — | 2,107,050 |
| Ryan Spencer | PSU | 165,000 | — | 2,107,050 |
| Ryan Spencer | Option | 231,000 | 12.48 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Scott MyersIndependent · Board Chair · Compensation (Chair) | $100,000 | $63,480 | $167,157 | $0 | $0 | $330,637 |
| Peggy V. PhillipsIndependent · Audit · Compensation (Chair) · Not standing for re-election | 75,000 | 63,480 | 167,157 | 0 | 0 | 305,637 |
| Peter R. ParadisoIndependent · Compensation | 71,750 | 63,480 | 167,157 | 0 | 0 | 302,387 |
| Julie EastlandIndependent · Audit (Chair) · Not standing for re-election | 70,000 | 63,480 | 167,157 | 0 | 0 | 300,637 |
| Daniel L. KisnerIndependent · Nominating/Governance (Chair) · Compensation | 67,000 | 63,480 | 167,157 | 0 | 0 | 297,637 |
| Elaine SunIndependent · Audit | 60,000 | 63,480 | 167,157 | 0 | 0 | 290,637 |
| Brent MacGregorIndependent · Nominating/Governance | 55,000 | 63,480 | 167,157 | 0 | 0 | 285,637 |
| Francis R. CanoIndependent · Nominating/Governance | 55,000 | 63,480 | 167,157 | 0 | 0 | 285,637 |
| Lauren SilvernailIndependent · Audit (Chair) · Newly elected | 0 | 0 | 0 | 0 | 0 | 0 |
| Ryan SpencerEmployee director | 0 | 0 | 0 | 0 | 0 | 0 |
| Emilio EminiIndependent · Newly elected | 0 | 0 | 0 | 0 | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2024 |
|---|---|
| Cash retainers and fees | $553,750 |
| Equity awards (grant-date value) | $507,840 |
| All other compensation | $0 |
| Total cost of the board | $1,061,590 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Dynavax Technologies as a peer
Companies that benchmark against DVAX
17 companies name DVAX as a compensation peer
- ACADIA PHARMACEUTICALS INCACADFY2025
- Adaptimmune Therapeutics PLCADAPFY2024
- Arcutis Biotherapeutics, Inc.ARQTFY2025
- ARDELYX, INC.ARDXFY2025
- AVADEL PHARMACEUTICALS PLCAVDLFY2024
- BIOCRYST PHARMACEUTICALS INCBCRXFY2025
- CATALYST PHARMACEUTICALS, INC.CPRXFY2024
- CERUS CORPCERSFY2025
- Coherus Oncology, Inc.CHRSFY2025
- Emergent BioSolutions Inc.EBSFY2025
- GERON CORPGERNFY2025
- HARROW, INC.HROWFY2025
- MYRIAD GENETICS INCMYGNFY2025
- NOVAVAX INCNVAXFY2025
- Pacira BioSciences, Inc.PCRXFY2025
- SUPERNUS PHARMACEUTICALS, INC.SUPNFY2025
- Travere Therapeutics, Inc.TVTXFY2025
Each company listed discloses DVAX in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named DVAX in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2024
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
ALEC Alector, Inc.AGEN Agenus, Inc.PTCT PTC Therapeutics, Inc.FOLD Amicus Therapeutics, Inc.SUPN Supernus Pharmaceuticals, Inc.COLL Collegium Pharmaceuticals, Inc.TVTX Travere Therapeutics, Inc.CORT Corcept Therapeutics, Inc.IRWD Ironwood Pharmaceuticals, Inc.PCVX Vaxcyte, Inc.MNKD Mannkind Corp. Fibrogen, Inc.EXEL Exelixis, Inc.HRMY Harmony Biosciences, Inc.EGRX Eagle Pharmaceuticals, Inc.PCRX Pacira BioSciences, Inc.ACAD Acadia Pharmaceuticals, Inc.NVAX Novavax, Inc.VIR Vir Biotechnology, Inc.IONS Ionis Pharmaceuticals, Inc.
Peer reciprocity
The companies Dynavax Technologies names as compensation peers that name it back in their own disclosed peer groups.
Supernus Pharmaceuticals, Inc. (SUPN)215Travere Therapeutics, Inc. (TVTX)216Pacira BioSciences, Inc. (PCRX)217Acadia Pharmaceuticals, Inc. (ACAD)218Novavax, Inc. (NVAX)219
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Exelixis, Inc. | 2025 | Michael Morrissey | $1,306,040 | $30,539,552 | $0 | $1,382,591 | $33,239,183 |
| 2 | PTC Therapeutics, Inc. | 2025 | Matthew Klein | 958,500 | 16,593,800 | 4,399,760 | 1,294,000 | 23,266,326 |
| 3 | Supernus Pharmaceuticals, Inc. | 2025 | Jack Khattar | 1,036,000 | 6,535,029 | 7,031,545 | 846,930 | 15,501,557 |
| 4 | Corcept Therapeutics, Inc. | 2025 | Joseph Belanoff | 1,182,333 | 0 | 12,907,718 | 0 | 15,303,551 |
| 5 | Vaxcyte, Inc. | 2025 | Grant Pickering | 800,000 | 4,300,159 | 8,714,048 | 630,000 | 14,458,937 |
| 6 | Ionis Pharmaceuticals, Inc. | 2025 | Brett Monia | 1,051,776 | 8,444,838 | 1,438,105 | 0 | 13,350,777 |
| 7 | Pacira BioSciences, Inc. | 2025 | Frank Lee | 935,308 | 9,215,500 | 0 | 738,810 | 11,636,917 |
| 8 | Eagle Pharmaceuticals, Inc. | 2022 | Scott Tarriff | 848,940 | 9,011,197 | 0 | 636,705 | 10,520,577 |
| 9 | Mannkind Corp. | 2025 | Michael Castagna | 789,436 | 7,689,480 | 0 | 675,757 | 9,300,485 |
| 10 | Novavax, Inc. | 2025 | John Jacobs | 792,917 | 3,545,435 | 3,763,292 | 640,331 | 8,856,015 |
| 11 | Amicus Therapeutics, Inc. | 2024 | Bradley Campbell | 767,308 | 4,990,365 | 2,105,627 | 0 | 8,526,943 |
| 12 | Travere Therapeutics, Inc. | 2025 | Eric Dube | 854,250 | 3,314,520 | 3,309,384 | 964,125 | 8,457,151 |
| 13 | Acadia Pharmaceuticals, Inc. | 2025 | Catherine Owen Adams | 930,000 | 3,240,558 | 3,234,797 | 818,559 | 8,256,518 |
| 14 | Dynavax Technologies | 2024 | Ryan Spencer | 835,001 | 4,902,150 | 1,824,299 | 641,907 | 8,210,775 |
| 15 | Harmony Biosciences, Inc. | 2025 | Jeffrey Dayno | 743,600 | 1,976,520 | 4,599,000 | 558,000 | 7,899,535 |
| 16 | Vir Biotechnology, Inc. | 2025 | Marianne De Backer | 950,000 | 2,296,800 | 3,507,360 | 1,002,750 | 7,834,045 |
| 17 | Alector, Inc. | 2025 | Arnon Rosenthal | 678,100 | 422,876 | 558,216 | 325,488 | 1,995,018 |
| 18 | Ironwood Pharmaceuticals, Inc. | 2025 | Thomas McCourt | 867,568 | 411,696 | 0 | 650,676 | 1,948,390 |
| 19 | Collegium Pharmaceuticals, Inc. | 2025 | Vikram Karnani | 875,000 | 0 | 0 | 835,406 | 1,715,846 |
| 20 | Agenus, Inc. | 2025 | Garo Armen | 715,260 | 0 | 141,000 | 0 | 1,350,325 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Dynavax Technologies | 102.5% | Options 34 · RSU 33 · PSU 33 | Yes — Relative Total Stockholder Return (rTSR) ranking vs. Nasdaq Biotechnology Index | Alpine |
| Acadia Pharmaceuticals, Inc. | 110% | Options 50 · PSU 25 · RSU 25 | Yes | Frederic W. Cook & Co., Inc. (FW Cook) |
| Agenus, Inc. | 125% | Options 100 | not disclosed | Aon Radford |
| Alector, Inc. | 80% | not disclosed | not disclosed | Pearl Meyer & Partners, LLC |
| Amicus Therapeutics, Inc. | not disclosed | Option 33 · RSU 33 · PRSU 33 | Yes — TSR Goal | Pay Governance |
| Collegium Pharmaceuticals, Inc. | 127.3% | RSU 70 · PSU 30 | Yes — relative ranking of the total shareholder return (TSR) of the Company's common stock in 2025, 2026, 2027 and the cumulative three-year performance period (2025-2027) return relative to the TSR of peer companies within the S&P Pharmaceutical Select Industry Index | Alpine Rewards, LLC |
| Corcept Therapeutics, Inc. | Dr. Belanoff: 100%; Dr. Guyer: 120%; Mr. Maduck: 80%; Mr. Mokari: 100%; Mr. Robb: 100%% | Stock Options 100 | not disclosed | not disclosed |
| Eagle Pharmaceuticals, Inc. | 75% | PSU 75 · RSU 25 | Yes — Total Shareholder Return (TSR) relative to S&P 600 Biotech Select Index (rTSR) | Compensia |
| Exelixis, Inc. | 105% | PSU 50 · RSU 50 | Yes — 2025 Relative TSR Goal | Aon |
| Harmony Biosciences, Inc. | 100% | not disclosed | not disclosed | Pay Governance |
| Ionis Pharmaceuticals, Inc. | not disclosed | PRSU 40 · Option 30 · RSU 30 | Yes — Relative TSR | Aon |
| Ironwood Pharmaceuticals, Inc. | 100% | RSU 50 · PSU 50 | not disclosed | Alpine Rewards LLC |
| Mannkind Corp. | 107% | PSU 55 · RSU 45 | Yes — Total Stockholder Return (TSR) relative to Russell 3000 Pharmaceutical & Biotechnology Index | Mercer LLC |
| Novavax, Inc. | 95% | Options 50 · RSU 50 | not disclosed | Pearl Meyer |
| Pacira BioSciences, Inc. | 90% | RSU 80 · PSU 20 | No | Aon |
| PTC Therapeutics, Inc. | not disclosed | Option 50 · RSU 50 | Yes — TSR relative to Nasdaq Biotechnology Index | Frederic W. Cook & Co., Inc. |
| Supernus Pharmaceuticals, Inc. | not disclosed | not disclosed | No | Aon |
| Travere Therapeutics, Inc. | 150% | not disclosed | No | Aon |
| Vaxcyte, Inc. | 105% | not disclosed | not disclosed | Pay Governance |
| Vir Biotechnology, Inc. | 125% | Options 67 · RSU 33 | not disclosed | Semler Brossy |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2025 | 2025-06-11 | 88,358,585 | 7,283,834 | 938,871 | 92.38% | Passed |
| 2024 | 2024-04-11 | 88,138,468 | 3,105,543 | 232,291 | 96.35% | Passed |
| 2023 | 2023-05-26 | 76,588,270 | 6,298,635 | 403,756 | 92.4% | Passed |
| 2022 | 2022-04-04 | 67,697,574 | 4,551,027 | 272,285 | 93.7% | Passed |
| 2021 | 2021-04-06 | 52,481,077 | 2,483,790 | 268,274 | 95.02% | Passed |
| 2020 | 2020-05-28 | 46,279,881 | 3,848,208 | 201,991 | 91.95% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2025 | 2025-06-11 | 92.38%a |
| 2024 | 2024-04-11 | 96.35%b |
| 2023 | 2023-05-26 | 92.4%c |
a. Voting standard not stated in the filing.
b. Approved under the standard stated in the filing — “Abstentions have the same effect as negative votes.”.
c. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2024 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Joseph Anthony Metzinger | VP, Chief Accounting Officer | 2025-05-12 | A | 38,182 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Joseph Anthony Metzinger | VP, Chief Accounting Officer | 2025-05-12 | A | 31,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Scott Myers | Director | 2025-06-11 | A | 5,758 | 0 | 0 | Common | Form 4 ↗ |
| Francis R. Cano | Director | 2025-06-11 | A | 28,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Francis R. Cano | Director | 2025-06-11 | A | 5,758 | 0 | 0 | Common | Form 4 ↗ |
| Brent MacGregor | Director | 2025-06-11 | A | 28,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Elaine Sun | Director | 2025-06-11 | A | 28,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brent MacGregor | Director | 2025-06-11 | A | 5,758 | 0 | 0 | Common | Form 4 ↗ |
| Elaine Sun | Director | 2025-06-11 | A | 5,758 | 0 | 0 | Common | Form 4 ↗ |
| Emilio Emini | Director | 2025-06-11 | A | 7,125 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Emilio Emini | Director | 2025-06-11 | A | 1,439 | 0 | 0 | Common | Form 4 ↗ |
| Peter R. Paradiso | Director | 2025-06-11 | A | 5,758 | 0 | 0 | Common | Form 4 ↗ |
| Daniel L. Kisner | Director | 2025-06-11 | A | 28,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Daniel L. Kisner | Director | 2025-06-11 | A | 5,758 | 0 | 0 | Common | Form 4 ↗ |
| Lauren Silvernail | Director | 2025-06-11 | A | 7,125 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Lauren Silvernail | Director | 2025-06-11 | A | 1,439 | 0 | 0 | Common | Form 4 ↗ |
| Scott Myers | Director | 2025-06-11 | A | 28,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Peter R. Paradiso | Director | 2025-06-11 | A | 28,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Deep Track Biotechnology Master Fund, Ltd. | Greater-than-10% holder | 2025-08-21 | D | 1,094,994 | 11 | 12,077,784 | Common | Form 4 ↗ |
| Deep Track Biotechnology Master Fund, Ltd. | Greater-than-10% holder | 2025-08-22 | D | 970,143 | 11 | 10,273,814 | Common | Form 4 ↗ |
| Scott Myers | Director | 2025-08-22 | A | 3,800 | 11 | 41,116 | Common | Form 4 ↗ |
| David Novack | President & COO | 2025-12-23 | D | 22,620 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ryan Spencer | Director | 2025-12-23 | D | 55,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| John Slebir | SVP General Counsel | 2025-12-23 | A | 16,667 | — | — | Common | Form 4 ↗ |
| John Slebir | SVP General Counsel | 2025-12-23 | A | 33,750 | — | — | Common | Form 4 ↗ |
| David Novack | President & COO | 2025-12-23 | A | 18,788 | — | — | Common | Form 4 ↗ |
| Kelly MacDonald | SVP and CFO | 2025-12-23 | D | 15,477 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kelly MacDonald | SVP and CFO | 2025-12-23 | A | 14,141 | — | — | Common | Form 4 ↗ |
| Kelly MacDonald | SVP and CFO | 2025-12-23 | A | 15,477 | — | — | Common | Form 4 ↗ |
| Joseph Anthony Metzinger | VP, Chief Accounting Officer | 2025-12-23 | D | 12,727 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ryan Spencer | Director | 2025-12-23 | D | 45,333 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ryan Spencer | Director | 2025-12-23 | A | 156,250 | — | — | Common | Form 4 ↗ |
| David Novack | President & COO | 2025-12-23 | A | 22,620 | — | — | Common | Form 4 ↗ |
| John Slebir | SVP General Counsel | 2025-12-23 | D | 16,667 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Novack | President & COO | 2025-12-23 | A | 60,625 | — | — | Common | Form 4 ↗ |
| Ryan Spencer | Director | 2025-12-23 | A | 45,333 | — | — | Common | Form 4 ↗ |
| Joseph Anthony Metzinger | VP, Chief Accounting Officer | 2025-12-23 | A | 12,727 | — | — | Common | Form 4 ↗ |
| Kelly MacDonald | SVP and CFO | 2025-12-23 | D | 14,141 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Novack | President & COO | 2025-12-23 | D | 18,788 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ryan Spencer | Director | 2025-12-23 | A | 55,000 | — | — | Common | Form 4 ↗ |
| John Slebir | SVP General Counsel | 2025-12-23 | A | 14,141 | — | — | Common | Form 4 ↗ |
| John Slebir | SVP General Counsel | 2025-12-23 | D | 14,141 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kelly MacDonald | SVP and CFO | 2025-12-23 | A | 37,500 | — | — | Common | Form 4 ↗ |
| Ryan Spencer | Director | 2025-12-24 | D | 138,168 | 15 | 2,125,024 | Common | Form 4 ↗ |
| John Slebir | SVP General Counsel | 2025-12-24 | D | 32,502 | 15 | 499,881 | Common | Form 4 ↗ |
| David Novack | President & COO | 2025-12-24 | D | 48,107 | 15 | 739,886 | Common | Form 4 ↗ |
| David Novack | President & COO | 2025-12-24 | A | 10,000 | 10 | 104,700 | Common | Form 4 ↗ |
| Joseph Anthony Metzinger | VP, Chief Accounting Officer | 2025-12-24 | D | 5,598 | 15 | 86,097 | Common | Form 4 ↗ |
| David Novack | President & COO | 2025-12-24 | A | 20,000 | 7 | 136,100 | Common | Form 4 ↗ |
| David Novack | President & COO | 2025-12-24 | D | 10,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Novack | President & COO | 2025-12-24 | D | 20,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Novack | President & COO | 2025-12-24 | D | 30,000 | 15 | 464,700 | Common | Form 4 ↗ |
| Kelly MacDonald | SVP and CFO | 2025-12-24 | D | 36,141 | 15 | 555,849 | Common | Form 4 ↗ |
| David Novack | President & COO | 2026-01-15 | D | 85,655 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Novack | President & COO | 2026-01-15 | D | 114,000 | 16 | 1,782,960 | Common, open-market sale | Form 4 ↗ |
| David Novack | President & COO | 2026-01-15 | D | 8,345 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Novack | President & COO | 2026-01-15 | D | 20,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Novack | President & COO | 2026-01-15 | A | 94,000 | 10 | 984,180 | Common | Form 4 ↗ |
| David Novack | President & COO | 2026-01-15 | A | 20,000 | 7 | 136,100 | Common | Form 4 ↗ |
| David Novack | President & COO | 2026-02-10 | D | 37,576 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Novack | President & COO | 2026-02-10 | D | 22,620 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Novack | President & COO | 2026-02-10 | D | 93,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Novack | President & COO | 2026-02-10 | D | 150,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Novack | President & COO | 2026-02-10 | D | 150,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Novack | President & COO | 2026-02-10 | D | 56,364 | — | — | Common | Form 4 ↗ |
| Francis R. Cano | Director | 2026-02-10 | D | 22,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lauren Silvernail | Director | 2026-02-10 | D | 42,750 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Brent MacGregor | Director | 2026-02-10 | D | 22,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Brent MacGregor | Director | 2026-02-10 | D | 25,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Brent MacGregor | Director | 2026-02-10 | D | 50,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Brent MacGregor | Director | 2026-02-10 | D | 21,829 | — | — | Common | Form 4 ↗ |
| Daniel L. Kisner | Director | 2026-02-10 | D | 28,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniel L. Kisner | Director | 2026-02-10 | D | 25,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniel L. Kisner | Director | 2026-02-10 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniel L. Kisner | Director | 2026-02-10 | D | 1,500 | — | — | Common | Form 4 ↗ |
| Elaine Sun | Director | 2026-02-10 | D | 28,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Elaine Sun | Director | 2026-02-10 | D | 22,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Elaine Sun | Director | 2026-02-10 | D | 11,250 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Scott Myers | Director | 2026-02-10 | D | 28,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Scott Myers | Director | 2026-02-10 | D | 22,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Scott Myers | Director | 2026-02-10 | D | 16,875 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Scott Myers | Director | 2026-02-10 | D | 45,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Scott Myers | Director | 2026-02-10 | D | 31,204 | — | — | Common | Form 4 ↗ |
| Scott Myers | Director | 2026-02-10 | D | 3,800 | — | — | Common | Form 4 ↗ |
| Emilio Emini | Director | 2026-02-10 | D | 42,750 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kelly MacDonald | SVP and CFO | 2026-02-10 | D | 70,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kelly MacDonald | SVP and CFO | 2026-02-10 | D | 350,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kelly MacDonald | SVP and CFO | 2026-02-10 | D | 46,430 | — | — | Common | Form 4 ↗ |
| Joseph Anthony Metzinger | VP, Chief Accounting Officer | 2026-02-10 | D | 25,455 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Joseph Anthony Metzinger | VP, Chief Accounting Officer | 2026-02-10 | D | 7,129 | — | — | Common | Form 4 ↗ |
| John Slebir | SVP General Counsel | 2026-02-10 | D | 28,283 | — | — | Derivative, Class A Common | Form 4 ↗ |
| John Slebir | SVP General Counsel | 2026-02-10 | D | 16,666 | — | — | Derivative, Class A Common | Form 4 ↗ |
| John Slebir | SVP General Counsel | 2026-02-10 | D | 88,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| John Slebir | SVP General Counsel | 2026-02-10 | A | 42,424 | — | — | Common | Form 4 ↗ |
| John Slebir | SVP General Counsel | 2026-02-10 | D | 69,634 | — | — | Common | Form 4 ↗ |
| Ryan Spencer | Director | 2026-02-10 | D | 55,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ryan Spencer | Director | 2026-02-10 | D | 225,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ryan Spencer | Director | 2026-02-10 | D | 250,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ryan Spencer | Director | 2026-02-10 | D | 400,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ryan Spencer | Director | 2026-02-10 | A | 136,000 | — | — | Common | Form 4 ↗ |
| Ryan Spencer | Director | 2026-02-10 | D | 379,620 | — | — | Common | Form 4 ↗ |
| David Novack | President & COO | 2026-02-10 | D | 63,334 | — | — | Common | Form 4 ↗ |
| David Novack | President & COO | 2026-02-10 | A | 56,364 | — | — | Common | Form 4 ↗ |
| David Novack | President & COO | 2026-02-10 | A | 67,860 | — | — | Common | Form 4 ↗ |
| Francis R. Cano | Director | 2026-02-10 | D | 25,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Francis R. Cano | Director | 2026-02-10 | D | 25,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Francis R. Cano | Director | 2026-02-10 | D | 42,663 | — | — | Common | Form 4 ↗ |
| Daniel L. Kisner | Director | 2026-02-10 | D | 22,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniel L. Kisner | Director | 2026-02-10 | D | 22,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniel L. Kisner | Director | 2026-02-10 | D | 22,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniel L. Kisner | Director | 2026-02-10 | D | 25,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniel L. Kisner | Director | 2026-02-10 | D | 21,829 | — | — | Common | Form 4 ↗ |
| Elaine Sun | Director | 2026-02-10 | D | 45,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Elaine Sun | Director | 2026-02-10 | D | 29,865 | — | — | Common | Form 4 ↗ |
| Scott Myers | Director | 2026-02-10 | D | 22,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kelly MacDonald | SVP and CFO | 2026-02-10 | D | 90,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| John Slebir | SVP General Counsel | 2026-02-10 | D | 70,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| John Slebir | SVP General Counsel | 2026-02-10 | D | 80,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| John Slebir | SVP General Counsel | 2026-02-10 | D | 42,424 | — | — | Common | Form 4 ↗ |
| John Slebir | SVP General Counsel | 2026-02-10 | D | 50,000 | — | — | Common | Form 4 ↗ |
| John Slebir | SVP General Counsel | 2026-02-10 | A | 50,000 | — | — | Common | Form 4 ↗ |
| Ryan Spencer | Director | 2026-02-10 | D | 280,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ryan Spencer | Director | 2026-02-10 | D | 165,000 | — | — | Common | Form 4 ↗ |
| Deep Track Biotechnology Master Fund, Ltd. | Greater-than-10% holder | 2026-02-10 | D | 15,726,349 | — | — | Common | Form 4 ↗ |
| John Slebir | SVP General Counsel | 2026-02-10 | D | 70,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ryan Spencer | Director | 2026-02-10 | D | 130,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Francis R. Cano | Director | 2026-02-10 | D | 22,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Novack | President & COO | 2026-02-10 | D | 150,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Novack | President & COO | 2026-02-10 | D | 67,860 | — | — | Common | Form 4 ↗ |
| Kelly MacDonald | SVP and CFO | 2026-02-10 | D | 42,424 | — | — | Common | Form 4 ↗ |
| Emilio Emini | Director | 2026-02-10 | D | 7,125 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ryan Spencer | Director | 2026-02-10 | D | 350,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Novack | President & COO | 2026-02-10 | D | 95,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Novack | President & COO | 2026-02-10 | D | 150,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ryan Spencer | Director | 2026-02-10 | D | 90,667 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ryan Spencer | Director | 2026-02-10 | D | 231,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ryan Spencer | Director | 2026-02-10 | D | 50,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ryan Spencer | Director | 2026-02-10 | D | 136,000 | — | — | Common | Form 4 ↗ |
| Kelly MacDonald | SVP and CFO | 2026-02-10 | D | 65,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kelly MacDonald | SVP and CFO | 2026-02-10 | D | 100,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kelly MacDonald | SVP and CFO | 2026-02-10 | A | 46,430 | — | — | Common | Form 4 ↗ |
| Kelly MacDonald | SVP and CFO | 2026-02-10 | D | 28,283 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kelly MacDonald | SVP and CFO | 2026-02-10 | D | 15,476 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Emilio Emini | Director | 2026-02-10 | D | 10,075 | — | — | Common | Form 4 ↗ |
| Francis R. Cano | Director | 2026-02-10 | D | 22,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Francis R. Cano | Director | 2026-02-10 | D | 28,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Brent MacGregor | Director | 2026-02-10 | D | 22,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Brent MacGregor | Director | 2026-02-10 | D | 22,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Brent MacGregor | Director | 2026-02-10 | D | 28,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lauren Silvernail | Director | 2026-02-10 | D | 7,125 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lauren Silvernail | Director | 2026-02-10 | D | 10,075 | — | — | Common | Form 4 ↗ |
| John Slebir | SVP General Counsel | 2026-02-10 | D | 300,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Elaine Sun | Director | 2026-02-10 | D | 22,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kelly MacDonald | SVP and CFO | 2026-02-10 | D | 60,204 | — | — | Common | Form 4 ↗ |
| Ryan Spencer | Director | 2026-02-10 | A | 165,000 | — | — | Common | Form 4 ↗ |
| Kelly MacDonald | SVP and CFO | 2026-02-10 | A | 42,424 | — | — | Common | Form 4 ↗ |
| Joseph Anthony Metzinger | VP, Chief Accounting Officer | 2026-02-10 | D | 31,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (219 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Ryan Spencer. DEF 14A, filed 2025-04-17. Section “Executive Compensation” · page 67. As printed: 8,210,775. View filing ↗
- Section 01, David Novack. DEF 14A, filed 2025-04-17. Section “Executive Compensation”. As printed: 3,731,687. View filing ↗
- Section 01, John Slebir. DEF 14A, filed 2025-04-17. Section “Executive Compensation”. As printed: 2,847,447. View filing ↗
- Section 01, Kelly MacDonald. DEF 14A, filed 2025-04-17. Section “Executive Compensation”. As printed: 2,626,267. View filing ↗
- Section 01, Robert Janssen. DEF 14A, filed 2025-04-17. Section “Executive Compensation”. As printed: 2,283,533. View filing ↗
- Section 03, John Slebir OPTION. DEF 14A. Section “Executive Compensation” · grants of plan-based awards table.
- Section 03, Ryan Spencer PSU. DEF 14A. Section “Executive Compensation” · grants of plan-based awards table.
- Section 03, Kelly MacDonald PSU. DEF 14A. Section “Executive Compensation” · grants of plan-based awards table.
- Section 03, David Novack . DEF 14A. Section “Executive Compensation” · grants of plan-based awards table.
- Section 03, Kelly MacDonald . DEF 14A. Section “Executive Compensation” · grants of plan-based awards table.
- Section 03, John Slebir PSU. DEF 14A. Section “Executive Compensation” · grants of plan-based awards table.
- Section 03, Kelly MacDonald OPTION. DEF 14A. Section “Executive Compensation” · grants of plan-based awards table.
- Section 03, Ryan Spencer OPTION. DEF 14A. Section “Executive Compensation” · grants of plan-based awards table.
- Section 03, Ryan Spencer . DEF 14A. Section “Executive Compensation” · grants of plan-based awards table.
- Section 03, Robert Janssen OPTION. DEF 14A. Section “Executive Compensation” · grants of plan-based awards table.
- Section 03, David Novack OPTION. DEF 14A. Section “Executive Compensation” · grants of plan-based awards table.
- Section 03, Robert Janssen . DEF 14A. Section “Executive Compensation” · grants of plan-based awards table.
- Section 03, Robert Janssen PSU. DEF 14A. Section “Executive Compensation” · grants of plan-based awards table.
- Section 03, John Slebir . DEF 14A. Section “Executive Compensation” · grants of plan-based awards table.
- Section 03, David Novack PSU. DEF 14A. Section “Executive Compensation” · grants of plan-based awards table.
- Section 08, Scott Myers. DEF 14A, filed 2025-04-17. Section “Director Compensation”. As printed: 330,637. View filing ↗
- Section 08, Peggy V. Phillips. DEF 14A, filed 2025-04-17. Section “Director Compensation”. As printed: 305,637. View filing ↗
- Section 08, Peter R. Paradiso. DEF 14A, filed 2025-04-17. Section “Director Compensation”. As printed: 302,387. View filing ↗
- Section 08, Julie Eastland. DEF 14A, filed 2025-04-17. Section “Director Compensation”. As printed: 300,637. View filing ↗
- Section 08, Daniel L. Kisner. DEF 14A, filed 2025-04-17. Section “Director Compensation”. As printed: 297,637. View filing ↗
- Section 08, Elaine Sun. DEF 14A, filed 2025-04-17. Section “Director Compensation”. As printed: 290,637. View filing ↗
- Section 08, Brent MacGregor. DEF 14A, filed 2025-04-17. Section “Director Compensation”. As printed: 285,637. View filing ↗
- Section 08, Francis R. Cano. DEF 14A, filed 2025-04-17. Section “Director Compensation”. As printed: 285,637. View filing ↗
- Section 08, Lauren Silvernail. DEF 14A, filed 2025-04-17. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Ryan Spencer. DEF 14A, filed 2025-04-17. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Emilio Emini. DEF 14A, filed 2025-04-17. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Joseph Anthony Metzinger 2025-05-12. Form 4, filed 2025-05-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph Anthony Metzinger 2025-05-12. Form 4, filed 2025-05-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Myers 2025-06-11. Form 4, filed 2025-06-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Francis R. Cano 2025-06-11. Form 4, filed 2025-06-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Francis R. Cano 2025-06-11. Form 4, filed 2025-06-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brent MacGregor 2025-06-11. Form 4, filed 2025-06-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elaine Sun 2025-06-11. Form 4, filed 2025-06-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brent MacGregor 2025-06-11. Form 4, filed 2025-06-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elaine Sun 2025-06-11. Form 4, filed 2025-06-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Emilio Emini 2025-06-11. Form 4, filed 2025-06-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Emilio Emini 2025-06-11. Form 4, filed 2025-06-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Peter R. Paradiso 2025-06-11. Form 4, filed 2025-06-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel L. Kisner 2025-06-11. Form 4, filed 2025-06-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel L. Kisner 2025-06-11. Form 4, filed 2025-06-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lauren Silvernail 2025-06-11. Form 4, filed 2025-06-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lauren Silvernail 2025-06-11. Form 4, filed 2025-06-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Myers 2025-06-11. Form 4, filed 2025-06-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Peter R. Paradiso 2025-06-11. Form 4, filed 2025-06-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Deep Track Biotechnology Master Fund, Ltd. 2025-08-21. Form 4, filed 2025-08-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Deep Track Biotechnology Master Fund, Ltd. 2025-08-22. Form 4, filed 2025-08-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Myers 2025-08-22. Form 4, filed 2025-08-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Novack 2025-12-23. Form 4, filed 2025-12-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ryan Spencer 2025-12-23. Form 4, filed 2025-12-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Slebir 2025-12-23. Form 4, filed 2025-12-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Slebir 2025-12-23. Form 4, filed 2025-12-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Novack 2025-12-23. Form 4, filed 2025-12-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kelly MacDonald 2025-12-23. Form 4, filed 2025-12-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kelly MacDonald 2025-12-23. Form 4, filed 2025-12-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kelly MacDonald 2025-12-23. Form 4, filed 2025-12-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph Anthony Metzinger 2025-12-23. Form 4, filed 2025-12-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ryan Spencer 2025-12-23. Form 4, filed 2025-12-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ryan Spencer 2025-12-23. Form 4, filed 2025-12-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Novack 2025-12-23. Form 4, filed 2025-12-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Slebir 2025-12-23. Form 4, filed 2025-12-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Novack 2025-12-23. Form 4, filed 2025-12-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ryan Spencer 2025-12-23. Form 4, filed 2025-12-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph Anthony Metzinger 2025-12-23. Form 4, filed 2025-12-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kelly MacDonald 2025-12-23. Form 4, filed 2025-12-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Novack 2025-12-23. Form 4, filed 2025-12-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ryan Spencer 2025-12-23. Form 4, filed 2025-12-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Slebir 2025-12-23. Form 4, filed 2025-12-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Slebir 2025-12-23. Form 4, filed 2025-12-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kelly MacDonald 2025-12-23. Form 4, filed 2025-12-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ryan Spencer 2025-12-24. Form 4, filed 2025-12-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Slebir 2025-12-24. Form 4, filed 2025-12-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Novack 2025-12-24. Form 4, filed 2025-12-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Novack 2025-12-24. Form 4, filed 2025-12-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph Anthony Metzinger 2025-12-24. Form 4, filed 2025-12-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Novack 2025-12-24. Form 4, filed 2025-12-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Novack 2025-12-24. Form 4, filed 2025-12-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Novack 2025-12-24. Form 4, filed 2025-12-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Novack 2025-12-24. Form 4, filed 2025-12-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kelly MacDonald 2025-12-24. Form 4, filed 2025-12-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Novack 2026-01-15. Form 4, filed 2026-01-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Novack 2026-01-15. Form 4, filed 2026-01-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Novack 2026-01-15. Form 4, filed 2026-01-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Novack 2026-01-15. Form 4, filed 2026-01-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Novack 2026-01-15. Form 4, filed 2026-01-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Novack 2026-01-15. Form 4, filed 2026-01-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Novack 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Novack 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Novack 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Novack 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Novack 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Novack 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Francis R. Cano 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lauren Silvernail 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brent MacGregor 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brent MacGregor 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brent MacGregor 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brent MacGregor 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel L. Kisner 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel L. Kisner 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel L. Kisner 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel L. Kisner 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elaine Sun 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elaine Sun 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elaine Sun 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Myers 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Myers 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Myers 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Myers 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Myers 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Myers 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Emilio Emini 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kelly MacDonald 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kelly MacDonald 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kelly MacDonald 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph Anthony Metzinger 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph Anthony Metzinger 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Slebir 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Slebir 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Slebir 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Slebir 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Slebir 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ryan Spencer 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ryan Spencer 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ryan Spencer 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ryan Spencer 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ryan Spencer 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ryan Spencer 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Novack 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Novack 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Novack 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Francis R. Cano 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Francis R. Cano 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Francis R. Cano 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel L. Kisner 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel L. Kisner 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel L. Kisner 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel L. Kisner 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel L. Kisner 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elaine Sun 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elaine Sun 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Myers 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kelly MacDonald 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Slebir 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Slebir 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Slebir 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Slebir 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Slebir 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ryan Spencer 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ryan Spencer 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Deep Track Biotechnology Master Fund, Ltd. 2026-02-10. Form 4, filed 2026-02-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Slebir 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ryan Spencer 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Francis R. Cano 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Novack 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Novack 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kelly MacDonald 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Emilio Emini 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ryan Spencer 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Novack 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Novack 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ryan Spencer 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ryan Spencer 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ryan Spencer 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ryan Spencer 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kelly MacDonald 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kelly MacDonald 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kelly MacDonald 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kelly MacDonald 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kelly MacDonald 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Emilio Emini 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Francis R. Cano 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Francis R. Cano 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brent MacGregor 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brent MacGregor 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brent MacGregor 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lauren Silvernail 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lauren Silvernail 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Slebir 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elaine Sun 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kelly MacDonald 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ryan Spencer 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kelly MacDonald 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph Anthony Metzinger 2026-02-10. Form 4, filed 2026-02-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-17. Item 5.07 · say-on-pay result. As reported: 92.38% (votes for as printed: 88,358,585). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-05-24. Item 5.07 · say-on-pay result. As reported: 96.35% (votes for as printed: 88,138,468). View filing ↗
- Section 06, 2023 vote. Form 8-K, filed 2023-05-26. Item 5.07 · say-on-pay result. As reported: 92.4% (votes for as printed: 76,588,270). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 553,750 + equity 507,840 + all other 0 = 1,061,590, summed across the director compensation table rows.
- Exelixis, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-15. CEO total compensation as printed in Exelixis, Inc.'s own proxy. As printed: 33,239,183. View filing ↗
- PTC Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-20. CEO total compensation as printed in PTC Therapeutics, Inc.'s own proxy. As printed: 23,266,326. View filing ↗
- Supernus Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Supernus Pharmaceuticals, Inc.'s own proxy. As printed: 15,501,557. View filing ↗
- Corcept Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Corcept Therapeutics, Inc.'s own proxy. As printed: 15,303,551. View filing ↗
- Vaxcyte, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Vaxcyte, Inc.'s own proxy. As printed: 14,458,937. View filing ↗
- Ionis Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Ionis Pharmaceuticals, Inc.'s own proxy. As printed: 13,350,777. View filing ↗
- Pacira BioSciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Pacira BioSciences, Inc.'s own proxy. As printed: 11,636,917. View filing ↗
- Eagle Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2023-05-01. CEO total compensation as printed in Eagle Pharmaceuticals, Inc.'s own proxy. As printed: 10,520,577. View filing ↗
- Mannkind Corp., Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Mannkind Corp.'s own proxy. As printed: 9,300,485. View filing ↗
- Novavax, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Novavax, Inc.'s own proxy. As printed: 8,856,015. View filing ↗
- Amicus Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-24. CEO total compensation as printed in Amicus Therapeutics, Inc.'s own proxy. As printed: 8,526,943. View filing ↗
- Travere Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Travere Therapeutics, Inc.'s own proxy. As printed: 8,457,151. View filing ↗
- Acadia Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Acadia Pharmaceuticals, Inc.'s own proxy. As printed: 8,256,518. View filing ↗
- Dynavax Technologies (subject), Section 10b CEO total. DEF 14A, filed 2025-04-17. CEO total compensation as printed in Dynavax Technologies's own proxy. As printed: 8,210,775. View filing ↗
- Harmony Biosciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-03. CEO total compensation as printed in Harmony Biosciences, Inc.'s own proxy. As printed: 7,899,535. View filing ↗
- Vir Biotechnology, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-16. CEO total compensation as printed in Vir Biotechnology, Inc.'s own proxy. As printed: 7,834,045. View filing ↗
- Alector, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Alector, Inc.'s own proxy. As printed: 1,995,018. View filing ↗
- Ironwood Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Ironwood Pharmaceuticals, Inc.'s own proxy. As printed: 1,948,390. View filing ↗
- Collegium Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Collegium Pharmaceuticals, Inc.'s own proxy. As printed: 1,715,846. View filing ↗
- Agenus, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Agenus, Inc.'s own proxy. As printed: 1,350,325. View filing ↗
- Section 10a, Supernus Pharmaceuticals, Inc. reciprocity. DEF 14A. Supernus Pharmaceuticals, Inc. names Dynavax Technologies in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Travere Therapeutics, Inc. reciprocity. DEF 14A. Travere Therapeutics, Inc. names Dynavax Technologies in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Pacira BioSciences, Inc. reciprocity. DEF 14A. Pacira BioSciences, Inc. names Dynavax Technologies in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Acadia Pharmaceuticals, Inc. reciprocity. DEF 14A. Acadia Pharmaceuticals, Inc. names Dynavax Technologies in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Novavax, Inc. reciprocity. DEF 14A. Novavax, Inc. names Dynavax Technologies in its own disclosed peer group (read from its most recent proxy). View filing ↗